The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems, providing an alternative to comparator products and lowering price ...
Novartis is running out of options in its bid to defend oral muscular sclerosis therapy Gilenya from early generic competition in the US. The US Court of Appeals for the Federal Circuit (CAFC) has ...
Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback